Of note, expression of anti-tumour immune response-related genes is down-regulated in both p16+/HPV- and HPV-/p16- tumours, consistent with the poorer survival outcomes of both these subgroups relative to p16+/HPV+. Here, CDKN2A is linked to neoplasm.